|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Embryonic Stem Cells |
1 Robert Koch Institute, Berlin, Germany
2 Arnold & Porter, LLP, Washington, District of Columbia
* To whom correspondence should be addressed. E-mail: LoeserP{at}rki.de.
| Abstract |
|---|
Research in human embryonic stem cells (hESCs) is a rapidly developing scientific field. In this study we collect and evaluate a thorough body of data on the current number of publicly disclosed hESC lines and the extent and impact of scientific work involving the use of these cells. These data contribute to the substantiation of the discussion on the current status of hESC research, provide a basis for the analysis of the status of such research, and uncover further needs in terms of registration, banking, standardization and tracing.
This article has been cited by other articles:
![]() |
X. Sun, X. Long, Y. Yin, Y. Jiang, X. Chen, W. Liu, W. Zhang, H. Du, S. Li, Y. Zheng, et al. Similar biological characteristics of human embryonic stem cell lines with normal and abnormal karyotypes Hum. Reprod., October 1, 2008; 23(10): 2185 - 2193. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. T. Scott and R. A. Reijo Pera The road to pluripotence: the research response to the embryonic stem cell debate Hum. Mol. Genet., April 15, 2008; 17(R1): R3 - R9. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Unger, H. Skottman, P. Blomberg, M. Sirac Dilber, and O. Hovatta Good manufacturing practice and clinical-grade human embryonic stem cell lines Hum. Mol. Genet., April 15, 2008; 17(R1): R48 - R53. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
